PHIA Stock Chart & Stats
€23.00
€0.20(0.88%)
At close: 4:00 PM EDT
€23.00
€0.20(0.88%)
Day’s Range― - ―
52-Week Range€20.60 - €27.60
Previous CloseN/A
Volume0.00
Average Volume (3M)15.00
Market Cap
€23.56B
Enterprise Value€32.86B
Total Cash (Recent Filing)€1.79B
Total Debt (Recent Filing)€7.46B
Price to Earnings (P/E)20.7
Beta1.00
Next Earnings
Nov 03, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.16
Shares Outstanding982,884,770
10 Day Avg. Volume32
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)2.02
Price to Sales (P/S)1.24
P/FCF Ratio24.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.64
Revenue Forecast (FY)€18.15B
Bulls Say, Bears Say
Bulls Say
Record Order Book And Resilient DemandResilient orders and a record equipment backlog provide visibility into future equipment revenue and support utilization of Philips’ service ecosystem. This strengthens planning and investment capacity over the next several quarters, although conversion timing can vary by project.
Personal Health Growth And Product InnovationPersonal Health is showing strong growth alongside favorable product mix and market-share gains, giving Philips a profitable consumer-health contributor alongside hospital businesses. Continued launches can reinforce brand strength and diversify the company’s revenue base.
Productivity Gains And Improving LeverageProductivity execution is generating tangible savings while lower leverage improves financial resilience and investment flexibility. If sustained, these gains can help offset inflation, support margins, and strengthen Philips’ ability to fund innovation and customer programs.
Bears Say
Volatile Profitability And Cash ConversionThe return to profit and positive cash generation has not yet established a consistent earnings pattern. Prior losses and declining free cash flow indicate that operating performance and cash conversion remain vulnerable, limiting confidence in the durability of the recovery.
China Procurement And Inflation Pressure MarginsChina’s procurement dynamics can reduce pricing power in health systems, while elevated input costs pressure gross and operating margins. Together, these forces may require continued productivity actions and create a durable execution burden across affected businesses.
Unresolved Respironics Legal And Regulatory ExposureUnresolved legal and regulatory proceedings create an ongoing source of uncertainty beyond Philips’ operating plan. Potential effects on future results, management attention, and financial flexibility make the recovery less predictable until these matters are resolved.
Koninklijke Philips News
PHIA FAQ
What was Koninklijke Philips’s price range in the past 12 months?
Koninklijke Philips lowest stock price was €20.60 and its highest was €27.60 in the past 12 months.
What is Koninklijke Philips’s market cap?
Koninklijke Philips’s market cap is €23.56B.
When is Koninklijke Philips’s upcoming earnings report date?
Koninklijke Philips’s upcoming earnings report date is Nov 03, 2026 which is in 5 days.
How were Koninklijke Philips’s earnings last quarter?
Koninklijke Philips released its earnings results on Jul 27, 2026. The company reported €0.498 earnings per share for the quarter, beating the consensus estimate of €0.359 by €0.139.
Is Koninklijke Philips overvalued?
According to Wall Street analysts Koninklijke Philips’s price is currently Overvalued.
Does Koninklijke Philips pay dividends?
Koninklijke Philips does not currently pay dividends.
What is Koninklijke Philips’s EPS estimate?
Koninklijke Philips’s EPS estimate is 0.35.
How many shares outstanding does Koninklijke Philips have?
Koninklijke Philips has 982,884,770 shares outstanding.
What happened to Koninklijke Philips’s price movement after its last earnings report?
Koninklijke Philips reported an EPS of €0.498 in its last earnings report, beating expectations of €0.359. Following the earnings report the stock price went up 0.877%.
Which hedge fund is a major shareholder of Koninklijke Philips?
Currently, no hedge funds are holding shares in DE:PHIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Koninklijke Philips Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.27%
12-Months-Change
Fundamentals
Return on Equity
10.05%
Trailing 12-Months
Asset Growth
-1.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Koninklijke Philips
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
PHIA Company Deck
PHIA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and financial tone: key growth metrics (comparable sales ~4%), strong order momentum (rolling 12‑month +5%), record equipment order book, robust Personal Health performance, notable commercial wins and continued productivity delivery supported the narrative. However, meaningful near‑term headwinds remain — elevated cost inflation, China centralized procurement pressure, D&T margin weakness ex‑refund, and timing/phasing of large cloud/platform deals — some of which depress near‑term underlying margins and introduce execution risk for the back‑loaded margin recovery. On balance, the positives (growth, order book, productivity progress, balance‑sheet improvement and reiterated guidance) outweigh the lowlights, but management highlighted areas requiring continued execution.View all DE:PHIA earnings summariesTechnical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
GE Healthcare Technologies Inc
―